metformin has been researched along with Steatorrhea in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Steatorrhea: A condition that is characterized by chronic fatty DIARRHEA, a result of abnormal DIGESTION and/or INTESTINAL ABSORPTION of FATS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The data suggest that improvement of the insulin sensitivity with metformin may improve the liver disease in patients with non-alcoholic steatohepatitis." | 9.11 | Metformin in the treatment of patients with non-alcoholic steatohepatitis. ( Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z, 2004) |
| "The data suggest that improvement of the insulin sensitivity with metformin may improve the liver disease in patients with non-alcoholic steatohepatitis." | 5.11 | Metformin in the treatment of patients with non-alcoholic steatohepatitis. ( Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uygun, A | 1 |
| Kadayifci, A | 1 |
| Isik, AT | 1 |
| Ozgurtas, T | 1 |
| Deveci, S | 1 |
| Tuzun, A | 1 |
| Yesilova, Z | 1 |
| Gulsen, M | 1 |
| Dagalp, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metformin and Steatorrhea
| Article | Year |
|---|---|
Metformin in the treatment of patients with non-alcoholic steatohepatitis.
Topics: Adult; Blood Glucose; C-Peptide; Female; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; | 2004 |